These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4277620)

  • 21. Inhibition of brain monoamine oxidase by 1,2,4-trisubstituted 5-imidazolones.
    Kumar S; Pandey BR; Parmar SS; Gallagher JR; Mayer GG
    Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):163-6. PubMed ID: 6729247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inhibition by monoamine oxidase inhibitors of substrate induction of liver tryptophan pyrrolase and increase in brain serotonin].
    Samsonova ML; Oksenkrug GF
    Vopr Med Khim; 1972; 18(2):198-202. PubMed ID: 4679586
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor.
    Grahame-Smith DG
    Br J Pharmacol; 1971 Dec; 43(4):856-64. PubMed ID: 4261561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of the inhibition of monoamine oxidase on daily oscillation of the serotonin content of the brain].
    Montanaro N; Casoli R; Babbini M
    Arch Ital Sci Farmacol; 1965; 15(1):84-6. PubMed ID: 5871028
    [No Abstract]   [Full Text] [Related]  

  • 25. Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour.
    Green AR; Youdim MB; Grahame-Smith DG
    Neuropharmacology; 1976 Mar; 15(3):173-9. PubMed ID: 132619
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of monoamine oxidase isoenzymes in rat motor activity after rubidium chloride treatment [proceedings].
    Acobettro RI; Ribas B; Ortiz T; Torres JT
    Biochem Soc Trans; 1979 Jun; 7(3):534-6. PubMed ID: 446854
    [No Abstract]   [Full Text] [Related]  

  • 27. [Inhibiting action of some derivatives of pyrazolinone on metabolic inactivation of 5-hydroxytryptamine].
    Patané S; Arrigo Reina R
    Boll Soc Ital Biol Sper; 1969 Aug; 45(16):1079-81. PubMed ID: 5374942
    [No Abstract]   [Full Text] [Related]  

  • 28. Short-term erythrosine B-induced inhibition of the brain regional serotonergic activity suppresses motor activity (exploratory behavior) of young adult mammals.
    Dalal A; Poddar MK
    Pharmacol Biochem Behav; 2009 Jun; 92(4):574-82. PubMed ID: 19264092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor effects of serotonin in the central nervous system.
    Gerson SC; Baldessarini RJ
    Life Sci; 1980 Oct; 27(16):1435-51. PubMed ID: 6160367
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of iron deficiency on brain monoamine metabolism and the behavioural responses to increased brain 5-hydroxytryptamine and dopamine synthesis [proceedings].
    Green AR; Youdim MB
    Br J Pharmacol; 1977 Mar; 59(3):470P-471P. PubMed ID: 843712
    [No Abstract]   [Full Text] [Related]  

  • 31. [Central effects of betamezide].
    Mikhaĭlova TV; Gilev AP; Khavronina-Gureeva ZP
    Farmakol Toksikol; 1969; 32(6):652-6. PubMed ID: 5381593
    [No Abstract]   [Full Text] [Related]  

  • 32. [3,4,5-trimethoxybenzoic acid hydrazides with anti-monoamine-oxidase activity].
    Mazzone G; Arrigo Reina R
    Boll Soc Ital Biol Sper; 1970 Dec; 46(24):1044-5. PubMed ID: 5519866
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function.
    Green AR; Grahame-Smith DG
    Neuropharmacology; 1975 Feb; 14(2):107-13. PubMed ID: 1153078
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats.
    Green AR; Grahame-Smith DG
    Neuropharmacology; 1974 Nov; 13(10-11):949-59. PubMed ID: 4437730
    [No Abstract]   [Full Text] [Related]  

  • 35. [Anti-monoamine-oxidase activity of some beta-acyl-phenylhydrazines].
    Arrigo Reina R; Mazzone G
    Boll Soc Ital Biol Sper; 1970 Dec; 46(24):1041-4. PubMed ID: 5519865
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical and animal experiments concerning the function of brain catecholamines.
    Matussek N
    Int Pharmacopsychiatry; 1971; 6(3):170-86. PubMed ID: 4950569
    [No Abstract]   [Full Text] [Related]  

  • 37. The differential neurochemical bases of the behaviours elicited by serotonergic agents and by the combination of a monoamine oxidase inhibitor and L-DOPA.
    Deakin JF; Dashwood MR
    Neuropharmacology; 1981 Feb; 20(2):123-30. PubMed ID: 6451815
    [No Abstract]   [Full Text] [Related]  

  • 38. The serotonin-catecholamine-dream bicycle: a clinical study.
    Wyatt RJ
    Biol Psychiatry; 1972 Aug; 5(1):33-64. PubMed ID: 4402884
    [No Abstract]   [Full Text] [Related]  

  • 39. The metabolism of 5-hydroxytryptamine in the methionine sulfoximine epileptogenic rat brain.
    Sellinger OZ; Dietz DD
    J Pharmacol Exp Ther; 1981 Jan; 216(1):77-82. PubMed ID: 6161244
    [No Abstract]   [Full Text] [Related]  

  • 40. [Data on the biochemical mechanism of action of antidepressive psychopharmacologic agents].
    Baconcini C; Muzio M
    Sist Nerv; 1971; 23(7):25-35. PubMed ID: 4360412
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.